When IDEXX Laboratories was added to the Finimize Portfolio in February 2025, the investment thesis was straightforward: the company isn't just selling veterinary diagnostic machines—it's selling the ongoing stream of consumables that make those machines work. That "razor-and-blades" model has paid off handsomely, with the stock climbing 53% since then. But after such a run, the question on many investors' minds is whether it's time to take profits and move on.
The business behind the stock
IDEXX is a leader in veterinary diagnostics, providing everything from blood analyzers to imaging equipment for animal clinics. The key to its business model is that once a clinic buys a machine, it becomes locked into buying IDEXX's proprietary test kits, slides, and other consumables—products that only work with IDEXX equipment. Think of it like a coffee machine that only accepts one brand of pod. This creates a sticky, recurring revenue stream that is highly predictable.
According to the original investment case, these repeat purchases account for nearly 90% of IDEXX's revenue. That's a powerful moat: clinics are unlikely to switch suppliers because doing so would mean replacing expensive equipment and retraining staff. The predictability of this revenue has been a key reason why IDEXX has been a favorite among growth investors.
Why the tide may be turning
Despite the strong fundamentals, the stock's 53% gain since February means much of the good news is already priced in. The company's growth rate, while steady, is not accelerating. In fact, as the veterinary diagnostics market matures, growth may slow to a more pedestrian pace. Investors who bought at the start of the year have enjoyed a fantastic return, but the risk-reward balance has shifted.
Valuation is a major concern. After such a run, IDEXX's price-to-earnings ratio is likely stretched relative to its historical average and to the broader market. For a company whose revenue growth is in the single digits to low double digits, paying a premium multiple may not be justified. When growth slows, high-multiple stocks often get hit hardest as investors re-rate them.
There's also the broader market backdrop. The recent rally in US stocks has been driven by optimism about policy clarity, but that doesn't mean every stock will keep climbing. Sector rotation can leave previously favored names behind, especially if investors shift toward cheaper, more cyclical areas.
What it means for investors
For those who bought IDEXX earlier this year, the decision to sell is not about whether the company is good—it clearly is. It's about whether the future returns justify the current price. With the stock up 53%, the margin of safety is gone. The original thesis—buying a high-quality compounder at a reasonable price—has played out. Now, the question is whether to lock in gains and redeploy capital elsewhere.
It's also worth noting that the veterinary diagnostics market is becoming more competitive. New entrants and technological shifts could erode IDEXX's pricing power over time. While the company has a strong brand and loyal customer base, no moat is permanent.
For investors who haven't yet bought in, chasing a stock after a 53% run is risky. The easy money has been made. Waiting for a pullback or a better entry point might be prudent. As always, it's important to consider your own investment horizon and risk tolerance. This is not a recommendation to sell or buy—just an analysis of the current situation.
Looking ahead
What should investors watch next? Key indicators include quarterly earnings reports, especially any signs of slowing consumable sales growth. Also, watch for any changes in the competitive landscape or regulatory environment that could affect IDEXX's business. The company's ability to maintain its ~90% recurring revenue mix will be crucial.
In the meantime, the broader market's reaction to political and economic events—like the Democratic sweep lifting bank and real estate stocks—shows how sentiment can shift quickly. For IDEXX, the story is still positive, but the risk-reward has changed. After a 53% gain, it may be time to call it a day and look for the next opportunity.
